Pulmatrix(PULM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PULM Pulmatrix

Closed 01-15 16:00:00 EST

2.53

+0.16

+6.75%

盘后2.53

+0.000.00%

16:04 EST

High2.70	Low2.35	Vol32.06K
Open2.35	D1 Closing2.37	Amplitude14.77%
Mkt Cap9.24M	Tradable Cap9.18M	Total Shares3.65M
T/O81.98K	T/O Rate0.88%	Tradable Shares3.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PULM","market":"US","secType":"STK","nameCN":"Pulmatrix","latestPrice":2.53,"timestamp":1768510800000,"preClose":2.37,"halted":0,"volume":32064,"hourTrading":{"tag":"盘后","latestPrice":2.53,"preClose":2.53,"latestTime":"16:04 EST","volume":1,"amount":2.53,"timestamp":1768511048275},"delay":0,"floatShares":3628121,"shares":3652285,"eps":-1.707265,"marketStatus":"Closed","change":0.16,"latestTime":"01-15 16:00:00 EST","open":2.35,"high":2.7,"low":2.35,"amount":81977.7394,"amplitude":0.147679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.707265,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768554000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1395374400000,"exchange":"NASDAQ","adjPreClose":2.37,"postHourTrading":{"tag":"盘后","latestPrice":2.53,"preClose":2.53,"latestTime":"16:04 EST","volume":1,"amount":2.53,"timestamp":1768511048275},"volumeRatio":1.904558},"requestUrl":"/m/hq/s/PULM","defaultTab":"news","newsList":[{"id":"2592907646","title":"BRIEF-Pulmatrix And Cullgen Continue To Pursue Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2592907646","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592907646?lang=en_us&edition=fundamental","pubTime":"2025-12-18 23:02","pubTimestamp":1766070142,"startTime":"0","endTime":"0","summary":"BRIEF-Pulmatrix And Cullgen Continue To Pursue Merger Dec 18 (Reuters) - Pulmatrix Inc PULM.O:PULMATRIX AND CULLGEN CONTINUE TO PURSUE MERGER WHILE GRANTING EACH OTHER WAIVERS TO EXPLORE ALTERNATIVESP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA212RRK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2592066779","title":"Pulmatrix and Cullgen Waive No-Solicitation Clause to Explore Alternatives Amid Ongoing Merger Approval Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2592066779","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592066779?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063117,"startTime":"0","endTime":"0","summary":"Pulmatrix and Cullgen have mutually agreed to waive the \"No Solicitation\" clause in their previously signed merger agreement, allowing both companies to explore alternative transactions while continuing to seek approval for their planned combination. The companies remain committed to working together toward completing the merger, which was approved by Pulmatrix stockholders in June 2025 but is still pending regulatory approval from the China Securities Regulatory Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief via PR Newswire  on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL2j7jGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2592990666","title":"Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990666?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA212RRK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2592906667","title":"Pulmatrix Inc - Co and Cullgen Waive \"No Solicitation\" Clause in Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906667?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:05","pubTimestamp":1766063100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA212RRK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2576702308","title":"Pulmatrix Reports Q3 2025 Results and Strategic Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2576702308","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576702308?lang=en_us&edition=fundamental","pubTime":"2025-10-17 11:57","pubTimestamp":1760673476,"startTime":"0","endTime":"0","summary":"Pulmatrix ( ($PULM) ) has released its Q3 earnings. Here is a breakdown of the information Pulmatrix presented to its investors. Pulmatrix, Inc. is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmatrix-reports-q3-2025-results-and-strategic-shift?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmatrix-reports-q3-2025-results-and-strategic-shift?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2575746616","title":"Pulmatrix reports Q3 EPS (24c) vs. (71c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2575746616","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575746616?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:21","pubTimestamp":1760617283,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pulmatrix-reports-q3-eps-24c-vs-71c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pulmatrix-reports-q3-eps-24c-vs-71c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PULM"],"gpt_icon":0},{"id":"2575745037","title":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745037","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745037?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:16","pubTimestamp":1760616971,"startTime":"0","endTime":"0","summary":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestmentOverviewPulmatrix Q3 2025 revenue decreased to $0, primarily due to winding down PUR1900 clinical trialCompany plans t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL2N3VX0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2575374572","title":"Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2575374572","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575374572?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:14","pubTimestamp":1760616841,"startTime":"0","endTime":"0","summary":"Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent increase over losses of $(0.71) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48246954/pulmatrix-q3-eps-0-24-up-from-0-71-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM"],"gpt_icon":0},{"id":"2575674515","title":"BRIEF-Pulmatrix Q3 EPS USD -0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2575674515","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575674515?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616354,"startTime":"0","endTime":"0","summary":"BRIEF-Pulmatrix Q3 EPS USD -0.24\n\n\nOct 16 (Reuters) - Pulmatrix Q3 operating expenses USD 866 thousand.\n\nQ3 income from operations USD -866 thousand\nQ3 net income USD -877 thousand","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nPLX8C43DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2575745153","title":"Pulmatrix Shareholders Approve Merger with Cullgen; Company Moves to Divest iSPERSE™ Technology and Migraine Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745153","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745153?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616334,"startTime":"0","endTime":"0","summary":"Pulmatrix Inc. provided an update on its proposed merger with Cullgen, a privately held, clinical-stage biopharmaceutical company focused on targeted protein degrader therapies for pain, cancer, and other diseases. The merger, if completed, would result in a Nasdaq-listed company featuring three degrader programs in Phase 1 clinical trials-two for cancer and one for acute and chronic pain, for which Cullgen recently completed enrollment. Pulmatrix is also in the process of potentially divesting its patent portfolio, including its proprietary iSPERSE inhalation technology and related clinical programs, such as its Phase 2 ready acute migraine program. The merger was approved by Pulmatrix stockholders at a special meeting on June 16, 2025, and remains subject to customary closing conditions. If finalized, Cullgen's business will continue as the business of the combined company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDLtlvnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pulmatrix Shareholders Approve Merger with Cullgen; Company Moves to Divest iSPERSE™ Technology and Migraine Assets","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2575745901","title":"Pulmatrix Q3 Operating Expenses USD 866 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745901?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616309,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nPLX8C43DE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PULM","BK4007"],"gpt_icon":0},{"id":"2575459047","title":"Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2575459047","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575459047?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA7PKWWF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2557537453","title":"Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2557537453","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557537453?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:16","pubTimestamp":1754482567,"startTime":"0","endTime":"0","summary":"Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46895894/pulmatrix-q2-eps-0-42-up-from-1-59-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM"],"gpt_icon":0},{"id":"2557937434","title":"Pulmatrix Inc. Reports Q2 2025 Results: Revenues Drop to $0 from $1.6M, R&D Expenses Plummet by $2.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2557937434","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557937434?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:06","pubTimestamp":1754481978,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL156rwk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PULM"],"gpt_icon":0},{"id":"2557744583","title":"Pulmatrix Inc. Advances Merger with Cullgen, Plans to Divest Inhalation Assets in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557744583","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557744583?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:06","pubTimestamp":1754481962,"startTime":"0","endTime":"0","summary":"Pulmatrix Inc. has announced progress in its proposed merger with Cullgen, a clinical-stage biopharmaceutical company specializing in targeted protein degrader therapies. The second quarter of 2025 saw significant advancements, including the effectiveness of the registration statement by the SEC and the approval of the merger by Pulmatrix's stockholders. The transaction is set to create a Nasdaq-listed company focusing on targeted protein degradation technology, with three degrader programs already in Phase 1 clinical trials. Pulmatrix is also planning to divest its proprietary iSPERSE technology and related clinical programs as part of the merger. The merger is expected to close in 2025, pending customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL54N7P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2557371098","title":"Pulmatrix Inc - Seeks Divestment of Isperse Patent Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2557371098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557371098?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:05","pubTimestamp":1754481904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLXED627C:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2557371092","title":"Pulmatrix Inc: to Also Potentially Divest Three Isperse Technology Related Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2557371092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557371092?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:05","pubTimestamp":1754481904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLXED627C:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2557371069","title":"Pulmatrix Q2 Operating Expenses USD 1.548 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2557371069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557371069?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:05","pubTimestamp":1754481904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLXED627C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2557371065","title":"Pulmatrix Inc - Proposed Merger With Cullgen Anticipated to Close in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557371065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557371065?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:05","pubTimestamp":1754481904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLXED627C:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0},{"id":"2557371015","title":"Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2557371015","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557371015?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:05","pubTimestamp":1754481904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUA90Z5HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PULM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pulmatrix.com","stockEarnings":[{"period":"1week","weight":0.0304},{"period":"1month","weight":-0.4552},{"period":"3month","weight":-0.4892},{"period":"6month","weight":-0.6184},{"period":"1year","weight":-0.5983},{"period":"ytd","weight":0.0628}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.289275},{"month":2,"riseRate":0.454545,"avgChangeRate":0.02992},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.136112},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.040652},{"month":5,"riseRate":0.416667,"avgChangeRate":0.027152},{"month":6,"riseRate":0.25,"avgChangeRate":-0.0597},{"month":7,"riseRate":0.25,"avgChangeRate":-0.076292},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.103916},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.033052},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.061729},{"month":11,"riseRate":0.416667,"avgChangeRate":0.146297},{"month":12,"riseRate":0.25,"avgChangeRate":-0.143561}],"exchange":"NASDAQ","name":"Pulmatrix","nameEN":"Pulmatrix"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pulmatrix(PULM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pulmatrix(PULM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pulmatrix,PULM,Pulmatrix股票,Pulmatrix股票老虎,Pulmatrix股票老虎国际,Pulmatrix行情,Pulmatrix股票行情,Pulmatrix股价,Pulmatrix股市,Pulmatrix股票价格,Pulmatrix股票交易,Pulmatrix股票购买,Pulmatrix股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pulmatrix(PULM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pulmatrix(PULM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}